Search
Close this search box.

New “Fast Facts” Scrutinizes ICER

Policymakers, providers and patients all feel the impact of The Institute for Clinical and Economic Review, whose ubiquitous cost-effectiveness reports can determine patients’ access to medicine.

Dignity & Dose Reduction

It’s hard to put a price on dignity. Just ask a patient dealing with PBA, or pseudobulbar affect.

IfPA Report Card: Health Plans Reject 1 in 3 High-Risk Heart Patients

Suffered a heart attack? Diagnosed with cardiovascular disease? Confirmed you have genetic high cholesterol?   None of that may matter to your health plan.   As new data reveals, insurers are still saying “no” to patients whose physicians prescribe a cholesterol-lowering PCSK9 inhibitor.  Even one in three at-risk patients who meet traditional criteria for coverage. […]